Maiko Midena discusses the key fundamentals to success when it comes to forecasting with large multinational pharmaceutical organizations.
Maiko Midena discusses some of the key fundamentals to success when it comes to forecasting with large multinational pharmaceutical organizations.
“The drive to implement bottom up forecasting for country to HQ is one that offers many benefits to an organisation. However, implementing change in such a political and technically challenging function has seen more failure than success”, David James (MD, J+D Consulting).
We create hundreds of strategic forecasting and operational planning models for many of the largest pharmaceutical companies year on year. These figures have increased consistently, certainly in the last 3–5 years; as scrutiny from pharmaceutical investors puts increasing pressure on revenue generation and growth.
Forecasting is a business-critical activity as it drives Investment Planning, Production, Marketing, Sales, R&D and essentially serves to mitigate investment risk. Despite the importance of forecasting, many of our clients openly admit that they lack time, resource, understanding and general capability to optimise their approach to forecasting. Thus, a less than optimal forecast is created. Often the forecast is based on several numbers without the context/evidence to support the prediction and those in senior positions are left to make less than confident decisions about the future of their brands.
Forecasting is becoming more challenging as revenues are becoming increasingly difficult to generate and individual markets are more complex. Complexity maybe derived from a diversification in indications, patent changes on products and opportunities in later lines of therapy/ or further combinations; all with a view to squeezing the last drop of profit from every potential brand investment opportunity.
Herein lies the problem, forecasting teams (more so outside the US and EU) are limited by resources and therefore, in some cases there are fundamental forecasting capability gaps, for example:
Improving the forecasting processes within an organization isn’t an overnight task it takes time, energy and motivation to overcome resistance and to improve capabilities. In order, for the forecasting process to work effectively we believe there are several pillars that support the overall optimum forecasting framework:
Forecasting is a complex multi-faceted discipline that needs to be managed and continually improved and adapted. The cost of getting it wrong can potentially damage any business. Best practice is attainable and overall confidence in robust decision making can be achieved. Overall those involved in forecasting need to appreciate that it’s more than just a number!
Maiko Midena is Director of Modelling & Forecasting, J+D Consulting, UK.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.